The director of the Alzheimer’s Prevention Clinic at Weill Cornell Medicine discussed the topics and ideas that clinicians should look forward to at the 2021 International Congress on the Future of Neurology.
"The first FDA approved drug for Alzheimer disease in almost 20 years was approved not long ago. There’s been a lot of controversy, but we can understand both sides. The pros and the cons. Dr. [Marwan] Sabagh will do that.”
Richard S. Isaacson, MD, currently serves as the director of the Alzheimer’s Prevention Clinic, Weill Cornell Memory Disorders Program, and Neurology Residency Training Program at Weill Cornell Medical College/New York-Presbyterian Hospital. The third annual International Congress on the Future of Neurology (IFN), held virtually from September 17-18, which will feature presentations on the most recent advancements in neurology, including that within Alzheimer disease (AD), with also feature Isaacson. As an expert within the space, he will be heading the “Updates in Alzheimer Disease” section of the meeting.
With several new developments within the field, including most notably, the FDA approval of the first disease-modifying therapy since 2003, there is good reason for buzz, according to Isaacson. He also emphasized raising education worldwide among clinicians regarding pushing healthy lifestyles to high-risk individuals and thus increasing AD prevention.
NeurologyLive sat down with Isaacson to get his inside perspective on why the clinician community should be excited for IFN 2021. He outlined several key talking points that are currently notable within the field, including the reasons for why women are more prone to AD and the role of genetics. Above everything, the theme of the meeting is geared towards the future of the space and how research is propelling it forward.